3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
8
Neoplasms
4
Pancreatic Neoplasms
3
Adenoma, Islet Cell
3
Carcinoma
2
Carcinoid Tumor
2
Adenoma
2
Pancreatic Neuroendocrine Tumors
1
Pancreatic Diseases
1
Neuroectodermal Tumors, Primitive
1
Neuroectodermal Tumors
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Gastro-enteropancreatic neuroendocrine tumor
1
Endocrine System Diseases
1
Endocrine Gland Neoplasms
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Carcinoma, Neuroendocrine
1
Adenocarcinoma
1
Interventions
repotrectinib
1
pralsetinib
1
lutetium Lu 177 dotatate
1
copper dotatate CU-64
1
anlotinib
1
alectinib
1
Sunitinib
1
Lutetium-177
1
Lutetium
1
E-7386
1
Cholecystectomy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Digestive System Neoplasms
×
Sunitinib
×
NET
×
Clear all
NCT01215578
2015-04-30
NET
Assistance Publique - Hôpitaux de Paris
Phase 2
Terminated
33 enrolled